Basit öğe kaydını göster

dc.contributor.authorTürkeş C.
dc.contributor.authorSöyüt H.
dc.contributor.authorBeydemir S.
dc.date.accessioned20.04.201910:49:12
dc.date.accessioned2019-04-20T21:44:13Z
dc.date.available20.04.201910:49:12
dc.date.available2019-04-20T21:44:13Z
dc.date.issued2014
dc.identifier.issn1734-1140
dc.identifier.urihttps://dx.doi.org/10.1016/j.pharep.2013.08.007
dc.identifier.urihttps://hdl.handle.net/20.500.12403/800
dc.description.abstractBackground: In this study, we investigated the in vitro effects of calcium channel blockers (nifedipine, nitrendipine, isradipine, and amlodipine besylate) on the activity of paraoxonase-1 (PON1). Methods: PON1 was purified from human serum using simple chromatographic methods, including DEAE-Sephadex anion-exchange and Sephadex G-200 gel filtration chromatography. Results: The calcium channel blockers decreased the in vitro PON1 activity. The inhibition mechanism of amlodipine besylate was noncompetitive, whereas nifedipine, nitrendipine, and isradipine were competitive inhibitors. Conclusions: Our results showed that calcium channel blockers exhibit inhibitory effects on PON1 at low concentrations. The IC50 values for nifedipine, nitrendipine, isradipine, and amlodipine besylate were determined to be 0.121 mM, 0.130 mM, 0.255 mM, and 0.304 mM, respectively, and the Ki constants were calculated to be 0.222 ± 0.049 mM, 0.151 ± 0.067 mM, 0.286 ± 0.137 mM, and 0.321 ± 0.002 mM, respectively. © 2014 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.en_US
dc.language.isoengen_US
dc.publisherElsevier B.V.
dc.relation.isversionof10.1016/j.pharep.2013.08.007
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAmlodipine besylate
dc.subjectIsradipine
dc.subjectNifedipine
dc.subjectNitrendipine
dc.subjectParaoxonase
dc.subjectamlodipine besylate
dc.subjectammonium sulfate
dc.subjectaryldialkylphosphatase 1
dc.subjectcalcium channel blocking agent
dc.subjectisradipine
dc.subjectnifedipine
dc.subjectnitrendipine
dc.subjectamlodipine
dc.subjectaryldialkylphosphatase
dc.subjectcalcium channel blocking agent
dc.subjectisradipine
dc.subjectnifedipine
dc.subjectPON1 protein, human
dc.subjectanion exchange chromatography
dc.subjectarticle
dc.subjectcompetitive inhibition
dc.subjectcontrolled study
dc.subjectdrug binding
dc.subjectdrug effect
dc.subjectdrug structure
dc.subjectenzyme activity
dc.subjectenzyme inhibition
dc.subjectfractionation
dc.subjectgel filtration chromatography
dc.subjecthuman
dc.subjectin vitro study
dc.subjectoxidative stress
dc.subjectantagonists and inhibitors
dc.subjectdrug effects
dc.subjectmetabolism
dc.subjectoxidative stress
dc.subjectAmlodipine
dc.subjectAryldialkylphosphatase
dc.subjectCalcium Channel Blockers
dc.subjectHumans
dc.subjectIsradipine
dc.subjectNifedipine
dc.subjectNitrendipine
dc.subjectOxidative Stress
dc.subjectAmlodipine besylate
dc.subjectIsradipine
dc.subjectNifedipine
dc.subjectNitrendipine
dc.subjectParaoxonase
dc.subjectamlodipine besylate
dc.subjectammonium sulfate
dc.subjectaryldialkylphosphatase 1
dc.subjectcalcium channel blocking agent
dc.subjectisradipine
dc.subjectnifedipine
dc.subjectnitrendipine
dc.subjectamlodipine
dc.subjectaryldialkylphosphatase
dc.subjectcalcium channel blocking agent
dc.subjectisradipine
dc.subjectnifedipine
dc.subjectPON1 protein, human
dc.subjectanion exchange chromatography
dc.subjectarticle
dc.subjectcompetitive inhibition
dc.subjectcontrolled study
dc.subjectdrug binding
dc.subjectdrug effect
dc.subjectdrug structure
dc.subjectenzyme activity
dc.subjectenzyme inhibition
dc.subjectfractionation
dc.subjectgel filtration chromatography
dc.subjecthuman
dc.subjectin vitro study
dc.subjectoxidative stress
dc.subjectantagonists and inhibitors
dc.subjectdrug effects
dc.subjectmetabolism
dc.subjectoxidative stress
dc.subjectAmlodipine
dc.subjectAryldialkylphosphatase
dc.subjectCalcium Channel Blockers
dc.subjectHumans
dc.subjectIsradipine
dc.subjectNifedipine
dc.subjectNitrendipine
dc.subjectOxidative Stress
dc.titleEffect of calcium channel blockers on paraoxonase-1 (PON1) activity and oxidative stressen_US
dc.typearticleen_US
dc.relation.journalPharmacological Reportsen_US
dc.contributor.departmentBayburt Universityen_US
dc.contributor.authorID55857860900
dc.contributor.authorID23502381000
dc.contributor.authorID6603903192
dc.identifier.volume66
dc.identifier.issue1
dc.identifier.startpage74
dc.identifier.endpage80
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster